The expansion includes new products under its Redecan and Good Supply brands, aimed at enhancing treatment options for healthcare professionals and patients.This initiative underscores Tilray’s commitment to the Australian market, a key growth area, according to Rajnish Ohri, President of International at Tilray Brands. The expanded portfolio will offer medical cannabis flower, extracts, vapes, and pastilles, enhancing access to high-potency, patient-focused solutions.While the broader market is down, with ...

Tilray stock price has just lost a key support: is a crash to $5 coming? Tilray stock price has just lost a key support: is a crash to $5 coming? Cannabis Author Crispus Nyaga Mar 19, 2026, 15:07 PM Tilray stock price has plummeted and lost crucial support as demand for cannabis companies wanes. TLRY dropped to $6.7 on Wednesday, its lowest level since August last year. It has slumped by 72% from its highest level last year. Tilray stock has slumped despite some key catalysts TLRY share price has dropped si ...

Watt stepped down as CEO later that year. His replacement James Arrow left under a year later. Watt’s fellow co-founder Martin Dickie announced his exit from the business in August last year.In January 2024, it emerged the company was to stop paying some of its hospitality staff the UK’s so-called real living wage to tackle increased costs.An open letter , posted online under the name ‘Punks With Purpose’ and signed by 76 former employees, claimed BrewDog was built around a “cult of personality” of Watt and ...

NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products. Tilray Medical has operated in Aus ...

Is Tilray Brands (NASDAQ: TLRY) finally bouncing back? After years of poor performance, the stock has climbed 7% over the past 12 months, which isn't bad by its standards. What's more, the market cheered the company's latest financial results. And with regulatory progress in the U.S. cannabis market, some see a bright future ahead for the pot grower. However, Tilray Brands still isn't worth investing in, not even close, in my view. Here's why I'd advise anyone to stay far away. Image source: Getty Images. ...

BRECKENRIDGE, Colo., March 18, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY is excited to announce that Cheba Hut 'Toasted' Subs will roll out Breckenridge Distillery products across 18 Colorado-based Cheba Hut restaurants. This will bring Breckenridge Distillery’s award-winning Bourbon Whiskey to all participating locations, with select restaurants in Boulder, Dillon, and one Denver location also pouri ...

Expanding into new segments can present a business and its investors with more plentiful growth opportunities. It can also be an effective way to be less dependent on a particular market or industry. For years, Tilray Brands (NASDAQ: TLRY) and other Canadian-based cannabis companies have been hopeful that the U.S. might soon legalize marijuana, which would open up a massive market for them. That hasn't happened, and it has resulted in some cannabis companies disappearing, becoming leaner, or, in Tilray's ...

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis, and wellness industries, today announced that the Company has entered into an asset purchase agreement to acquire certain strategic assets of BrewDog in the United States, including its brewery, pub, and hotel in Columbus, Ohio, as well as the pubs in New Albany, Ohio, Cl ...

Core Viewpoint - Tilray Brands is entering a strategic partnership with pharmaceutical entities in Germany to enhance its market presence and improve access to its products [1][7]. Group 1: Strategic Partnership - The partnership involves collaboration with Tilray Medical, CC Pharma, and 14U Pharma, aimed at expanding product offerings and pharmacy access [1][2]. - Effective April 1, 2026, the alliance will leverage CC Pharma's distribution network, which supports over 16,000 pharmacies in Germany [2]. Group 2: Market Position and Performance - The collaboration is expected to strengthen Tilray's position in the dynamic German healthcare market [3]. - Despite a slight downturn in the broader market, Tilray's stock is underperforming, indicating company-specific challenges [3][7]. Group 3: Recent Developments - Tilray recently launched a new American-style light beer, Pub Light, as part of its beverage portfolio expansion [4]. - The company has acquired BrewDog Brewing Australia Pty Ltd., including its Brisbane brewery and several BrewDog bar locations [4]. Group 4: Technical Analysis - The stock is trading 5.2% below its 20-day simple moving average (SMA) and 12.9% below its 50-day SMA, indicating a bearish trend [5]. - Over the past 12 months, shares have increased by 11.79%, with a neutral RSI of 40.00 and a MACD suggesting a potential bullish crossover [5][6]. Group 5: Earnings and Analyst Outlook - Tilray is expected to provide its next financial update on April 7, 2026 [8]. - The EPS estimate is a loss of 1 cent, with a revenue estimate of $203.15 million, up from $185.78 million [10]. - The stock carries a Hold Rating, with recent analyst moves including a neutral rating from Roth Capital and a lowered target to $10.00 [11]. Group 6: ETF Exposure - Tilray has significant weight in the Amplify Alternative Harvest ETF (NYSE:MJ) at 12.38%, indicating that ETF inflows or outflows could impact the stock [12].

Core Insights - Tilray Pharma has formed a strategic partnership with Tilray Medical, CC Pharma, and "gesund leben" cooperation to enhance its market presence in Germany [1][2][4] - The partnership aims to provide a comprehensive range of healthcare solutions, including prescription medications and medical cannabis, to pharmacies across Germany [2][5] Group 1: Partnership Details - The collaboration will take effect on April 1, 2026, focusing on improving pharmacy access and product availability [2] - The "gesund leben" cooperation includes approximately 3,600 member pharmacies, offering benefits such as digital access and competitive purchasing terms [3][8] - This partnership allows CC Pharma to access over 20% of German pharmacies, significantly expanding its market reach [4] Group 2: Market Context - Germany is identified as a crucial and dynamic healthcare market in Europe, making this partnership strategically significant for Tilray [4] - The alliance is expected to enhance service offerings and operational efficiency for pharmacies, thereby increasing customer traffic and sales [3][8] Group 3: Company Background - CC Pharma is a leading pharmaceutical distributor in Germany, serving over 16,000 pharmacies with a wide range of medicines [4][9] - Tilray Medical specializes in providing medical cannabis and has established itself as a significant supplier in the European market [10]